Risk relating to licenses and approvals for pharmaceuticals and insurance
First written in FY2016. 14 of 16 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2021: 2 of 14 companies on the "Worse" side.
16 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「During the current interim consolidated accounting period, there were no new business or other risks, nor any material changes in the business or other risks described in the securities report for the preceding fiscal year.」
製薬等の許認可リスクについて、重要な変更がないとしている。 - FY2020SoftenedAnnual report
「ヘルスケアセグメントにおいて、当社グループは、製薬開発及び販売等を営む子会社を有しております。」
少額短期保険事業の譲渡後、許認可リスクの説明対象から保険商品の開発・販売が外れ、製薬開発・販売等に範囲が縮小している。 - FY2020-Q3RestatedAnnual report
「During the 3rd quarter of the current consolidated fiscal year, there were no material changes in financial position, operating results or cash flows, including any abnormal fluctuations, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2020-Q2RestatedAnnual report
「当第２四半期連結累計期間において、財政状態、経営成績及びキャッシュ・フローの状況の異常な変動等または、前事業年度の有価証券報告書に記載した「事業等のリスク」について重要な変更はありません。」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2020-Q1RestatedAnnual report
「During the 1st quarter of the current consolidated fiscal year, there were no material changes in financial position, operating results or cash flows, including any abnormal fluctuations, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2019-Q3RestatedAnnual report
「During the 3rd quarter of the current consolidated fiscal year, there were no material changes in financial position, operating results or cash flows, including any abnormal fluctuations, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2019-Q2RestatedAnnual report
「当第２四半期連結累計期間において、財政状態、経営成績及びキャッシュ・フローの状況の異常な変動等または、前事業年度の有価証券報告書に記載した「事業等のリスク」について重要な変更はありません。」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2019-Q1RestatedAnnual report
「During the 1st quarter of the current consolidated fiscal year, there were no material changes in financial position, operating results or cash flows, including any abnormal fluctuations, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2018-Q3RestatedAnnual report
「During the 3rd quarter of the current consolidated fiscal year, there were no material changes in financial position, operating results or cash flows, including any abnormal fluctuations, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2018-Q2RestatedAnnual report
「During the cumulative consolidated period of the second quarter, there were no material changes in unusual fluctuations, etc., in financial position, operating results or cash flows, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2018-Q1RestatedAnnual report
「During the 1st quarter of the current consolidated fiscal year, there were no material changes in financial position, operating results or cash flows, including any abnormal fluctuations, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2017RestatedAnnual report
「The Group has subsidiaries engaged in pharmaceutical development and sales and in the development and sale of insurance products. Because these subsidiaries include businesses that require licenses and approvals from regulatory authorities to operate, administrative guidance or the revocation of licenses or approvals could materially affect the Group’s business performance and business plans.」
製薬・保険等の許認可、行政指導・取消しに伴うリスクを継続して記載している。 - FY2017-Q3RestatedAnnual report
「During the cumulative consolidated period of the third quarter, there were no material changes in unusual fluctuations, etc., in financial position, operating results or cash flows, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2017-Q2RestatedAnnual report
「During the cumulative consolidated period of the second quarter, there were no material changes in unusual fluctuations, etc., in financial position, operating results or cash flows, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2017-Q1RestatedAnnual report
「During the 1st quarter of the current consolidated fiscal year, there were no material changes in financial position, operating results or cash flows, including any abnormal fluctuations, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
製薬・保険等の許認可リスクについて、重要な変更はないとしている。 - FY2016First statedAnnual report
「The Group has subsidiaries engaged in pharmaceutical development and sales and in the development and sale of insurance products. Because these subsidiaries include businesses that require licenses and approvals from regulatory authorities to operate, administrative guidance or the revocation of licenses or approvals could materially affect the Group’s business performance and business plans.」
The Group identifies the potential impact of administrative guidance and license or approval revocation on subsidiaries whose businesses require regulatory authorization.